Factor XI Inhibitor

Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research.

ISIS 416858, a single-stranded antisense oligodeoxynucleotide, is a potent and selective inhibitor of FXI mRNA expression.

Vortosiran, a siRNA, is a blood coagulation factor XI synthesis reducer with anticoagulant activity.

BMS-962212 hydrochloride is a selective coagulation factor XIa inhibitor and acute antithrombotic agent. BMS-962212 hydrochloride can be used in the research of thrombosis.

Vortosiran sodium scrambled negative control is the sequence scrambled negative control of Vortosiran sodium.

Neutrophil elastase-IN-7 (Compound 12) is an effective inhibitor of neutrophil elastase (HNE), with an IC₅₀ value of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against various coagulation proteins, with the IC₅₀ values for thrombin, FXa, FXIa, and FXIIIa being 8.2, 12.7, 1.2, and 5.7 μM, respectively. Neutrophil elastase-IN-7 can be used for research on inflammation, innate immune responses, and tissue remodeling.

MK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research.

Vortosiran sodium, a siRNA, is a blood coagulation factor XI synthesis reducer with anticoagulant activity.

FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC₅₀ of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis.

Factor XI-IN-1 (Compound 27) is a factor XI activation inhibitor with an EC₅₀ of 25.14 nM.

FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with K_i values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases.

FXIa-IN-17 (Compound FE12) is a selective FXIa inhibitor with an IC₅₀ of 4.4 nM. FXIa-IN-17 effectively inhibits thrombus formation.

Factor XI-IN-2 is a Factor XI activation inhibitor with an IC₅₀ of 20 nM. Factor XI-IN-2 does not directly inhibit the enzymatic activity of FXIa, but specifically binds to the FXI enzyme precursor and allosterically inhibits the process by which it is activated by FXIIa. Factor XI-IN-2 inhibits thrombosis in the rabbit arteriovenous (AV) shunt thrombosis model. Factor XI-IN-2 can be used for the study of antithrombus.